|
HBS1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.65611968583335E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.15341070028308E-12 |
| Normal-vs-Stage2 |
1.035400E-04 |
| Normal-vs-Stage3 |
7.30304705598428E-13 |
| Normal-vs-Stage4 |
3.67199604056623E-11 |
| Stage1-vs-Stage2 |
3.848800E-01 |
| Stage1-vs-Stage3 |
1.115830E-01 |
| Stage1-vs-Stage4 |
9.530000E-02 |
| Stage2-vs-Stage3 |
9.425600E-02 |
| Stage2-vs-Stage4 |
6.257500E-02 |
| Stage3-vs-Stage4 |
6.789800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.18793863634892E-14 |
| Normal-vs-AfricanAmerican |
1.422020E-04 |
| Normal-vs-Asian |
1.33019999459805E-08 |
| Caucasian-vs-AfricanAmerican |
2.690000E-01 |
| Caucasian-vs-Asian |
8.447400E-01 |
| AfricanAmerican-vs-Asian |
3.824600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.25135490647699E-14 |
| Normal-vs-Female |
4.14990264374637E-12 |
| Male-vs-Female |
4.928300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.75649544593193E-11 |
| Normal-vs-Age(41-60Yrs) |
5.81978909508507E-13 |
| Normal-vs-Age(61-80Yrs) |
1.42969969196827E-10 |
| Normal-vs-Age(81-100Yrs) |
5.014300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.971400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.098600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.773600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.037000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.063400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.007400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.318400E-01 |
| Classical-VS-Follicular |
7.911600E-01 |
| Classical-VS-Other |
2.341200E-01 |
| Classical-VS-Normal |
1.91424653905869E-12 |
| Tall-VS-Follicular |
2.910000E-01 |
| Tall-VS-Other |
4.827800E-01 |
| Tall-VS-Normal |
5.33739999974969E-08 |
| Follicular-VS-Other |
3.105400E-01 |
| Follicular-VS-Normal |
2.62929999994554E-07 |
| Other-VS-Normal |
2.615900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.80210291134131E-11 |
| Normal-vs-N1 |
6.74271749545596E-12 |
| N0-vs-N1 |
6.350100E-02 |
|
|
